Latest Fate Therapeutics Inc. Stories

2013-10-09 11:39:15

New method for improving cord blood transplant success Starting with a discovery in zebrafish in 2007, Harvard Stem Cell Institute (HSCI) researchers have published initial results of a Phase Ib human clinical trial of a therapeutic that has the potential to improve the success of blood stem cell transplantation. This marks the first time, just nine short years after Harvard's major commitment to stem cell biology, that investigators have carried a discovery from the lab bench to the...

2011-02-21 16:42:00

SAN DIEGO, Feb. 21, 2011 /PRNewswire/ -- In parallel with announcing encouraging clinical data at the 2011 BMT Tandem Meetings from its ongoing proof-of-concept FT1050 Phase 1b trial, Fate Therapeutics announced that Paul A. Grayson, who has been president & CEO since April 2008, is leaving Fate to form a new company. "I am proud of the outstanding organization that I have assembled at Fate, and of the company's innovative product pipeline," noted Mr. Grayson. "This excellent news...

Word of the Day
  • Boughs or branches.
  • Warbling of birds in trees.